Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2019
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Apr 2019 The trial has been completed in UK, according to European Clinical Trials Database record.
- 31 Aug 2018 Biomarkers information updated
- 18 Oct 2017 Status changed from completed to discontinued.